# Shunichi Sugawara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shunichi-sugawara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,787 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 131 |
| Last Known Institution | Sendai Kousei Hospital |
| OpenAlex ID | https://openalex.org/A5080846994 |
| ORCID iD | https://orcid.org/0000-0002-3427-4558 |
| Works | 410 |

## Researcher papers

- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial](https://scholariq.org/papers/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-5-year/)
- [Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer](https://scholariq.org/papers/multisystem-immune-related-adverse-events-associated-with-immune-checkpoint/)
- [Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-versus-docetaxel-for-previously-treated-advanced-or/)
- [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer](https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Sendai Kousei Hospital](https://scholariq.org/institutions/sendai-kousei-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.